GI
INSY

Gradient Investments’s Insys Therapeutics, Inc. INSY Stock Holding History

Gradient Investments’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-434
Closed -$2K – 1063
2018
Q4 		$2K Buy
+434
New +$3.02K ﹤0.01% 838

Other funds holding INSY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Gradient Investments's INSY Position: Q1 2019 in Review

Gradient Investments sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 434 shares — an estimated $2K sold.

Gradient Investments first reported a position in INSY in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

  • Gradient Investments reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Gradient Investments sold 434 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
  • Gradient Investments first reported a position in Insys Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Gradient Investments's Insys Therapeutics, Inc. position peaked at $2K in Q4 2018.
  • 98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Gradient Investments's 13F filing for Q1 2019, filed 11 Apr 2019.